Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Liabilities (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Total Liabilities for 13 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 26.38% to $14.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Dec 2025, up 26.38% year-over-year, with the annual reading at $14.0 million for FY2025, 48.94% up from the prior year.
  • Total Liabilities hit $14.1 million in Q4 2025 for Vistagen Therapeutics, down from $14.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $19.8 million in Q3 2021 to a low of $6.6 million in Q3 2023.
  • Historically, Total Liabilities has averaged $11.6 million across 5 years, with a median of $10.8 million in 2021.
  • Biggest five-year swings in Total Liabilities: soared 55.29% in 2021 and later tumbled 44.07% in 2022.
  • Year by year, Total Liabilities stood at $10.6 million in 2021, then decreased by 14.43% to $9.0 million in 2022, then fell by 13.85% to $7.8 million in 2023, then skyrocketed by 43.71% to $11.2 million in 2024, then increased by 26.38% to $14.1 million in 2025.
  • Business Quant data shows Total Liabilities for VTGN at $14.1 million in Q4 2025, $14.6 million in Q3 2025, and $12.2 million in Q2 2025.